Vertex Pharmaceuticals Inc

NASDAQ: VRTX
$490.88
-$9.00 (-1.8%)
Real Time Data Delayed 15 Min.

VRTX Articles

Thursday’s top analyst upgrades, downgrades and initiations include Advanced Micro Devices, Comerica, General Mills, Mastercard and Vertex Pharmaceuticals.
A series of new Jefferies reports focus on four biotech stocks that have big upside potential, regardless of the political chatter.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ariad Pharmaceuticals, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M and Time Warner.
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
24/7 Wall St. has collected several big FDA decisions and imminent clinical trial results that should be coming up in the June quarter. We have added some color.
One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Facebook, First Solar, Hess, Texas Instruments, U.S. Steel, Vertex Pharmaceuticals and Infinera.
A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top biotech stocks.
Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and it went up smartly.
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.